<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809039</url>
  </required_header>
  <id_info>
    <org_study_id>MT-6345-E01</org_study_id>
    <secondary_id>2018-002478-39</secondary_id>
    <nct_id>NCT03809039</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MT-6345 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Investigate the Safety, Tolerability and Pharmacokinetics of
      MT-6345 in Healthy Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma terminal elimination half life (t½) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to 24 hours (AUC0-24h) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to the last measurable concentration (AUC0-last) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve over the dosing interval (AUC0-t) of MT-6345.</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss/F) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity factor (LF) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excreted amount of test compound (Ae) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excreted amount of test compound expressed as a percentage of the dose administered (Ae%) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of MT-6345</measure>
    <time_frame>up to 2 weeks after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-6345</intervention_name>
    <description>MT-6345</description>
    <arm_group_label>Multiple Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-6345 Placebo</intervention_name>
    <description>MT-6345 Placebo</description>
    <arm_group_label>Multiple Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose: MT-6345 &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Additional screening criteria check may apply for qualification:

          -  Able to provide written informed consent to participate in this study after reading
             the participant information sheet and Informed Consent Form (ICF), and after having
             the opportunity to discuss the study with the Investigator or designee.

          -  Healthy and free from clinically significant illness or disease as determined by
             medical history, physical examination, laboratory and other tests at Screening and Day
             -1.

          -  A body weight of ≥60 kg for males and ≥50 kg for females and a body mass index (BMI)
             (Quetelet index) ranging from 18 to 30.0 kg/m2 inclusive at Screening and Day -1.

          -  In the Investigator's opinion, subject is able to understand the nature of the study
             and any risks involved in participation, and willing to cooperate and comply with the
             Protocol restrictions and requirements.

        Exclusion Criteria:

        Additional screening criteria check may apply for qualification:

          -  Subjects with clinically significant (in the opinion of the Investigator) endocrine,
             thyroid, hepatic, respiratory, gastrointestinal, neurological, renal, cardiovascular
             disease, or history (within the last 5 years) of any significant psychiatric/psychotic
             illness disorder (including anxiety, depression and reactive depression).

          -  Female subjects who are pregnant (positive pregnancy test at Screening or Day -1) or
             lactating.

          -  Having previously received MT-6345 as part of this study.

          -  Clinically relevant abnormal medical history, physical findings or laboratory values
             at Screening or Day -1 that could interfere with the objectives of the study or the
             safety of the subject, as judged by the Investigator.

          -  Subjects who test positive for hepatitis B surface antigen, hepatitis B core antibody,
             hepatitis C antibody, human immunodeficiency virus (HIV)-1 or HIV-2 antibodies at
             Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development,</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitsubishi Tanabe Pharma Europe Ltd General Information, to prevent mis-communication,</last_name>
    <phone>please e-mail:</phone>
    <email>regulatory@mt-pharma-eu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City Name</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

